Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

(2023) Kausik K Ray et al.   Lancet Diabetes & Endocrinology

POOLED SAFETY ANALYSIS OF INCLISIRAN IN 3,576 PATIENTS WITH APPROXIMATELY 10,000 PERSON YEARS OF EXPOSURE FROM 7 TRIALS

(2023) R. Scott Wright et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

(2022) J Tamargo et al.   European Heart Journal-Cardiovascular Pharmacotherapy

Target Low-Density Lipoprotein-Cholesterol and Secondary Prevention for Patients with Acute Myocardial Infarction: A Korean Nationwide Cohort Study

(2022) Ju Hyeon Kim et al.   Journal of Clinical Medicine

Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab

(2022) Ulf Landmesser et al.   European Journal of Preventive Cardiology

2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

(2022) Donald M. Lloyd-Jones et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

(2022) Kausik K Ray et al.   EUROPEAN HEART JOURNAL

LDL-Cholesterol Lowering Strategies and Population Health - Time to Move to a Cumulative Exposure Model

(2020) Julia Brandts et al.   CIRCULATION

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

(2020) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction

(2020) Baris Gencer et al.   JAMA Cardiology

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019

(2020) Gregory A. Roth et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of Alirocumab on Mortality After Acute Coronary Syndromes

(2019) Philippe Gabriel Steg et al.   CIRCULATION

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

(2019) Shaun G. Goodman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels

(2018) Marc S. Sabatine et al.   JAMA Cardiology

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary

(2018) Scott M. Grundy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective

(2015) Tomas Jernberg et al.   EUROPEAN HEART JOURNAL

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE